The literature evidence clearly shows that, while treating advanced solid tumors, the therapeutic outcome of PD-1 pathway blockade is very well correlated with PD-L1 expression levels by the tumor cells and therefore stands as a prime model for targeted immunotherapies [7,8]. Here, CD274 is linked to neoplasm.